Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 10/20 | 0.49 |
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | RAB9A | P51151 | 6/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | G6PD | P11413 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3129032 | 1.00 | NQO2 (0.49) | NQO2MAPTRAB9AMAPK1ALDH1A1 | |
| SCHEMBL31031113 | 1.00 | NQO2 (0.49) | NQO2MAPTRAB9AMAPK1ALDH1A1 | |
| Sulfuric Acid SCHEMBL10827282 | 0.90 | ALDH1A1 (0.53) | NQO2MAPTRAB9AMAPK1ALDH1A1 | |
| Sulfuric Acid SCHEMBL10827277 | 0.90 | ALDH1A1 (0.53) | NQO2MAPTRAB9AMAPK1ALDH1A1 | |
| SCHEMBL28685743 | 0.84 | MAPT (0.45) | NQO2MAPTRAB9AMAPK1ALDH1A1 | |
| Phenazine SCHEMBL2873102 | 0.84 | MAPT (0.50) | NQO2MAPTRAB9AMAPK1ALDH1A1 | |
| Phenazine SCHEMBL10876543 | 0.84 | MAPT (0.50) | NQO2MAPTRAB9AMAPK1ALDH1A1 | |
| Phenazine SCHEMBL94396 | 0.84 | MAPT (0.50) | NQO2MAPTRAB9AMAPK1ALDH1A1 | |
| SCHEMBL197530 | 0.83 | NQO2 (0.75) | NQO2MAPTRAB9AMAPK1ALDH1A1 | |
| SCHEMBL4945159 | 0.83 | NQO2 (0.75) | NQO2MAPTRAB9AMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106676123-B | A kind of screening technique of glucose dehydrogenase mutant | 厦门大学 | 2019-10-22 | — | — | CN | claimed |
| EP-4188445-A1 | APPLICATION OF DIPYRRINATO-IRIDIUM COMPLEXES IN ANTI-TUMOR AND ANTI-BACTERIAL THERAPY | biolitec Unternehmensbeteiligungs II AG (AT) | 2023-06-07 | — | — | EP | disclosed |
| CN-106676123-B | A kind of screening technique of glucose dehydrogenase mutant | 厦门大学 | 2019-10-22 | — | — | CN | disclosed |
| CN-106795189-B | Platinum (IV) complexes with improved antitumor efficacy | VUAB制药股份有限公司 | 2019-05-07 | — | — | CN | disclosed |
| CN-106795189-A | Platinum (IV) complexes with improved antitumor efficacy | VUAB制药股份有限公司 | 2017-05-31 | — | — | CN | disclosed |
| WO-2013019982-A2 | BIOSENSING SYSTEM WITH EXTENDED LIFETIME VIA COFACTOR RECYCLING | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-02-07 | — | — | WO | disclosed |
| EP-2456435-A1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | The Board of Trustees of The Leland Stanford Junior University (US) | 2012-05-30 | — | — | EP | disclosed |
| WO-2011011514-A1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2011-01-27 | — | — | WO | disclosed |
| WO-2010078941-A1 | CALCIUMPHOSPHATE-BASED NANOPARTICLES AS CARRIER-SYSTEMS FOR PHOTODYNAMIC THERAPY | BIOLITEC AG (DE) | 2010-07-15 | — | — | WO | disclosed |
| EP-2084162-A2 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2007064759-A2 | INHIBITING TUMOUR CELL INVASION, METASTASIS AND ANGIOGENESIS THROUGH TARGETTING LEGUMAIN | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007059341-A2 | PYRAZOLOTHIAZOLE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| US-6790612-B2 | EXPRESSION VECTORS WHICH EVALUATES SENSITIVITY OF HEPATITIS VIRUS TO VIRICIDES/ENZYME INHIBITORS VIA MONITORING DECREASE OR INCREASE IN SECRETION OF ALKALINE PHOSPHATASE (SEAP) | AGOURON PHARMACEUTICALS, INC. | 2004-09-14 | — | — | US | disclosed |
| US-20030175692-A1 | Reporter gene system for use in cell-based assessment of inhibitors of the hepatitis C virus protease | AGOURON PHARMACEUTICALS, INC. | 2003-09-18 | — | — | US | disclosed |
| EP-1102992-A4 | REPORTER GENE SYSTEM FOR USE IN CELL-BASED ASSESSMENT OF INHIBITORS OF THE HEPATITIS C VIRUS PROTEASE | AGOURON PHARMA (US) | 2003-07-30 | — | — | EP | disclosed |
| US-6599738-B2 | Recombinant plasmid which comprises a Hepatitis C virus/secreted alkaline phosphatase (SEAP) gene construct operably linked to a promoter compatible with an RNA polymerase | AGOURON PHARMACEUTICALS, INC. | 2003-07-29 | — | — | US | disclosed |
| US-20030082518-A1 | Reporter gene system for use in cell-based assessment of inhibitors of the hepatitis C virus protease | AGOURON PHARMACEUTICALS, INC. | 2003-05-01 | — | — | US | disclosed |
| US-6280940-B1 | Reporter gene system for use in cell-based assessment of inhibitors of the Hepatitis C virus protease | AGOURON PHARMACEUTICALS, INC. | 2001-08-28 | — | — | US | disclosed |
| EP-1102992-A1 | REPORTER GENE SYSTEM FOR USE IN CELL-BASED ASSESSMENT OF INHIBITORS OF THE HEPATITIS C VIRUS PROTEASE | AGOURON PHARMACEUTICALS, INC. (US) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000008469-A1 | REPORTER GENE SYSTEM FOR USE IN CELL-BASED ASSESSMENT OF INHIBITORS OF THE HEPATITIS C VIRUS PROTEASE | AGOURON PHARMACEUTICALS, INC. (US) | 2000-02-17 | — | — | WO | disclosed |